113 related articles for article (PubMed ID: 8562349)
1. Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.
Hanauske AR; Catimel G; Aamdal S; ten Bokkel Huinink W; Paridaens R; Pavlidis N; Kaye SB; te Velde A; Wanders J; Verweij J
Br J Cancer; 1996 Feb; 73(3):397-9. PubMed ID: 8562349
[TBL] [Abstract][Full Text] [Related]
2. Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
McLeod HL; Murray LS; Wanders J; Setanoians A; Graham MA; Pavlidis N; Heinrich B; ten Bokkel Huinink WW; Wagener DJ; Aamdal S; Verweij J
Br J Cancer; 1996 Dec; 74(12):1944-8. PubMed ID: 8980394
[TBL] [Abstract][Full Text] [Related]
3. Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.
Kaplan S; Hanauske AR; Pavlidis N; Bruntsch U; te Velde A; Wanders J; Heinrich B; Verweij J
Br J Cancer; 1996 Feb; 73(3):403-5. PubMed ID: 8562351
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
Verweij J; Wanders J; Gil T; Schöffski P; Catimel G; te Velde A; de Mulder PH
Br J Cancer; 1996 Feb; 73(3):400-2. PubMed ID: 8562350
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.
Tolcher AW; Aylesworth C; Rizzo J; Izbicka E; Campbell E; Kuhn J; Weiss G; Von Hoff DD; Rowinsky EK
Ann Oncol; 2000 Mar; 11(3):333-8. PubMed ID: 10811501
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of rhizoxin.
Bissett D; Graham MA; Setanoians A; Chadwick GA; Wilson P; Koier I; Henrar R; Schwartsmann G; Cassidy J; Kaye SB
Cancer Res; 1992 May; 52(10):2894-8. PubMed ID: 1581905
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
Graham MA; Bissett D; Setanoians A; Hamilton T; Kerr DJ; Henrar R; Kaye SB
J Natl Cancer Inst; 1992 Apr; 84(7):494-500. PubMed ID: 1545439
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
[TBL] [Abstract][Full Text] [Related]
9. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W
Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
11. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study.
Tozer RG; Burdette-Radoux S; Berlanger K; Davis ML; Lohmann RC; Rusthoven JR; Wainman N; Zee B; Seymour L;
Invest New Drugs; 2002 Nov; 20(4):407-12. PubMed ID: 12448658
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
[TBL] [Abstract][Full Text] [Related]
14. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
Bakker M; Droz JP; Hanauske AR; Verweij J; van Oosterom AT; Groen HJ; Pacciarini MA; Domenigoni L; van Weissenbruch F; Pianezzola E; de Vries EG
Br J Cancer; 1998; 77(1):139-46. PubMed ID: 9459159
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent.
Hendriks HR; Plowman J; Berger DP; Paull KD; Fiebig HH; Fodstad O; Dreef-van der Meulen HC; Henrar RE; Pinedo HM; Schwartsmann G
Ann Oncol; 1992 Nov; 3(9):755-63. PubMed ID: 1450065
[TBL] [Abstract][Full Text] [Related]
16. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Pavlidis N; Aamdal S; Awada A; Calvert H; Fumoleau P; Sorio R; Punt C; Verweij J; van Oosterom A; Morant R; Wanders J; Hanauske AR
Cancer Chemother Pharmacol; 2000; 46(2):167-71. PubMed ID: 10972487
[TBL] [Abstract][Full Text] [Related]
17. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Lang F; Krauss G; Hejna M; Raderer M; Weinländer G; Depisch D; Scheithauer W
Br J Cancer; 1998 Sep; 78(5):673-8. PubMed ID: 9744509
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of bryostatin-1 in metastatic melanoma.
Bedikian AY; Plager C; Stewart JR; O'Brian CA; Herdman SK; Ross M; Papadopoulos N; Eton O; Ellerhorst J; Smith T
Melanoma Res; 2001 Apr; 11(2):183-8. PubMed ID: 11333129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
